Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 705564 in Healthy Males
NCT03123185Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 705564 in systemic lupus erythematosus (SLE) (14 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Participants With Drug-related Adverse Events up to 15 days, Area Under the Concentration-time Curve of BI 705564 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point up to 72 hours and 1 more. Started Apr 2017; status: completed.
02
Drugs
BI 705564
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03123185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123185.